Market Intelligence, Clinical Progress, and High-Purity Reagents for Promyelocytic Leukemia Protein (PML/TRIM19) Research and Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PML drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PML Recombinant Protein (RBCC Domain / Full-Length) High purity (>95%), Endotoxin Controlled. Sequence Verified. Optimized for solubility. |
View PML Products |
| Gene Delivery | PML Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study nuclear body dynamics. |
View PML Products |
| Benchmark Ab | Anti-PML Recombinant Antibody Recombinant positive control for immunofluorescence and western blot assays. |
View PML Products |
| Validator | PML siRNA Set For knockdown verification and specificity controls in functional assays. |
View PML Products |
| Related Target A | RARA (Retinoic Acid Receptor Alpha) PML-RARA fusion partner; critical for Acute Promyelocytic Leukemia (APL) research. |
View RARA Products |
| Related Target B | SUMO1 (Small Ubiquitin-Like Modifier 1) Crucial mediator of PML nuclear body assembly and arsenic-induced degradation. |
View SUMO1 Products |
| Related Target C | TP53 (p53 Tumor Suppressor) Interacts with PML-NBs to regulate cellular senescence and apoptosis. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein aggregation and poor solubility of the zinc-binding RBCC motif | Truncated and solubility-optimized recombinant domains verified by mass spectrometry and SDS-PAGE (>95% purity). |
| Monitoring intracellular PML nuclear body (PML-NB) formation | Lentiviral vectors expressing fluorescently tagged PML for real-time live-cell imaging and degradation assays. |
| Lack of highly specific positive controls | Sequence-defined recombinant anti-PML antibodies ensuring batch-to-batch reproducibility. |
| Off-target screening within the TRIM family | PML-specific siRNA knockdown sets and TRIM family homolog proteins for counter-screening. |
Live PML R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PML (Promyelocytic Leukemia protein, also known as TRIM19) remains a cornerstone of precision oncology. Historically defined by the PML-RARA fusion in Acute Promyelocytic Leukemia (APL), clinical strategies are rapidly expanding. While the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) represents one of the most successful targeted therapies in cancer history, current R&D is shifting toward targeting wild-type PML in solid tumors, cancer stem cells, and viral restriction pathways.
As the molecular mechanisms governing PML nuclear bodies (PML-NBs) become clearer, the next wave of drug discovery is focusing on novel small-molecule modulators, molecular glues, and PROTACs designed to selectively degrade or stabilize PML to overcome drug resistance in glioblastoma, leukemia stem cells, and immunotherapy-resistant solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Protein Degraders (PROTACs / Glues) | Academic Institutes, Biotech Startups | Solid Tumors, Therapy-Resistant AML | In vitro degradation assays (Need high-purity recombinant PML RBCC domain and SUMO1 proteins) |
| Small Molecule Inhibitors / Modulators | Pharmaceutical Developers | Glioblastoma, Cancer Stem Cells | High-throughput screening & binding assays (Need sequence-verified PML target proteins) |
| Combination Therapies (ATRA/ATO + Novel Agents) | Global Oncology Leaders | APL, Relapsed/Refractory Leukemias | Synergy and resistance mechanism validation (Need PML-RARA stable cell line construction via Lentivirus) |